78 148
[19]
Benderra MA, Aspeslagh S, Postel-Vinay S, et al. Acquired EGFR mutation as the potential resistance driver to crizotinib in a MET- mutated tumor. J Thorac Oncol 2016;11:e21–3.
[20]
Kwak EL, Ahronian LG, Siravegna G, et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cancer Discov 2015;5: 1271–81.
[21]
Palma NA, Ali SM, O’Connor J, et al. Durable response to crizotinib in a MET-amplified, KRAS-mutated carcinoma of unknown primary. Case Rep Oncol 2014;7:503–8.
[22]
Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31:181–6.
[23]
Schoffski P. Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somatic MET mutations. EORTC phase II trial 90101 ‘‘CREATE’’. Cancer Res 2016;76(14 Suppl):CT006.
[24]
Choueiri TK, Plimack ER, Arkenau H-T, et al. A single-armbiomarker- based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC). J Clin Oncol 2017;35(Suppl 6):436.
[25]
Li S, Shuch BM, Gerstein MB. Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations. PLoS Genet 2017;13:e1006685.
[26]
Linehan WM, Spellman PT, Ricketts CJ, et al. Comprehensive mo- lecular characterization of papillary renal-cell carcinoma. N Engl J Med 2016;374:135–45.
[27]
Young RJ, Waldeck K, Martin C, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res 2014;27:590–600.
[28]
Logan JE, Mostofizadeh N, Desai AJ, et al. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. An- ticancer Res 2013;33:2997–3004.
[29]
Kim KH, KimW, Howard TP, et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med 2015;21:1491–6.
[30]
Chan-Penebre E, Armstrong K, Drew A, et al. Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: in vitro and in vivo preclinical models. Mol Cancer Ther 2017;16:850–60.[31]
Kawano S, Grassian AR, Tsuda M, et al. Preclinical evidence of anti- tumor activity induced by EZH2 inhibition in human models of synovial sarcoma. PloS One 2016;11:e0158888.
[32]
Ali SM, Miller VA, Ross JS, Pal SK. Exceptional response on addition of everolimus to taxane in urothelial carcinoma bearing an NF2 mutation. Eur Urol 2015;67:1195–6.
[33]
Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124–8.[34]
Ball MW, Johnson MH, Gorin MA, et al. Clinical, pathologic, and genomic profiles of exceptional responders to anti–PD1 therapy in renal cell carcinoma. J Clin Oncol 2016;34:625.
[35]
Moreira RB, McKay RR, Xie W, et al. Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC). J Clin Oncol 2017;35(Suppl 6):482.
[36]
Albiges L, Guegan J, Le Formal A, et al. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res 2014;20:3411–21.
[37]
Stein MN, Hirshfield KM, Zhong H, Singer EA, Ali SM, Ganesan S. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib. Eur Urol 2015; 67:353–4.[38]
Vignot S, Frampton GM, Soria JC, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol 2013;31:2167–72.
[39]
Vignot S, Lefebvre C, Frampton GM, et al. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and tran- scriptional profiles. Eur J Cancer 2015;51:791–9.
[40]
Pal SK, Sonpavde G, Agarwal N, et al. Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma. Eur Urol 2017;72:557–64.[41]
Tannir NM, Jonasch E, Altinmakas E, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (the ESPN trial): a multicenter randomized phase 2 trial. J Clin Oncol 2014;32:4505.[42]
Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lan- cet Oncol 2016;17:378–88.E U R O P E A N U R O L O G Y 7 3 ( 2 0 1 8 ) 7 1 – 7 8
78